A 34-year-old male was admitted to the hospital with recurrent episodes of retrosternal chest pain, fatigue, and shortness of breath with an elevated troponin T. He had suffered an acute episode of myocarditis four years previously requiring hospital admission. He had no other relevant medical history and no family history of cardiac disease. He is a nonsmoker and consumed alcohol occasionally. Clinical examination was unremarkable and did not show any evidence of heart failure or systemic disease. ECG showed normal sinus rhythm without any ischemic changes, and chest X-ray showed no evidence of infection or heart failure. Routine blood tests including antinuclear antibody, creatinine kinase (CK), rheumatoid factor, and C-reactive protein were all within normal limits apart from an elevated cardiac troponin T with a peak value of 2700 ng/l (<14 ng/l). Further extensive inflammatory, viral, and autoimmune screening was carried out and found to be negative. Subsequent coronary angiogram showed normal coronary arteries, and transthoracic echocardiography demonstrated left ventricular ejection fraction (LVEF) >55% with trace mitral regurgitation. Cardiac magnetic resonance imaging (MRI) demonstrated extensive subepicardial and midwall
late enhancement typical of myocarditis in the anterior, lateral, and inferior walls along with extensive fibrosis with normal LVEF (Figure 1).

A short course of steroids and anti-inflammatory medication as an inpatient resulted in the resolution of his myocarditis symptoms. The troponin T level normalized and the patient was discharged with a plan to repeat cardiac MRI in six months. On follow-up as an outpatient, it was decided to refer the patient to rheumatology for an opinion regarding ongoing immunomodulatory therapy. At this juncture, the patient stated that he also had symptoms of stiffness and aching in his calf muscles for quite some time but he did not consider it to be relevant. Despite persistently normal skeletal muscle enzyme levels, an MRI of the lower legs was performed and this showed active myositis involving the gastrocnemius muscles bilaterally (Figure 2). As the patient was demonstrated to have ongoing myositis despite minimal symptoms, and as he had accrued significant myocardial scarring from previous episodes of myocarditis, it was decided to commence long-term immunomodulatory therapy in the form of methotrexate and prednisolone. Clinically, the patient reported a significant improvement in his symptoms and a repeat of the lower limb MRI demonstrated a significant interval improvement in his skeletal muscle myositis. Six months later, a repeat of the cardiac MRI demonstrated resolution of myocarditis along with persistent, stable, and extensive myocardial fibrosis and preserved LVEF (Figure 3). The patient is tolerating the immunomodulatory therapy well without major side effects, and he has returned to full-time work.

3. Discussion

We describe an elusive case of a young male with recurrent episodes of acute myocarditis presenting with chest pain and elevated troponin T. All biochemical, immune, and autoimmune tests were within normal limits. However, he described a long-standing and persistent history of calf aching and discomfort. Consequently, lower limb MRI revealed that the patient had active myositis of his gastrocnemius muscles. This unexpected finding demonstrated that this inflammatory myositis was not isolated to cardiac muscle and by definition was still active despite initial treatment. As this patient had already accrued significant myocardial scarring, the finding of active myositis demonstrated the need for more effective long-term immunomodulatory therapy in order to preserve cardiac function. Cardiac involvement in patients with skeletal myositis was first reported in 1899 [6]. Subclinical conduction abnormalities and arrhythmias discovered by ECG are considered to be more frequent.

![Figure 1: Cardiac MRI showing extensive subepicardial and midwall late enhancement typical of myocarditis in the anterior, lateral, and inferior walls.](image1)

![Figure 2: MRI of the left leg showing patchy increased STIR signal in the muscles but predominately involving the gastrocnemius muscles.](image2)
than clinically manifest heart involvement [5]. The number of reported cases of clinically overt cardiac involvement in patients with myositis has increased recently, largely due to the increased use of noninvasive sensitive tests such as troponin [5]. The overall incidence of heart involvement in myositis patients ranges from 6% to 75% depending on the type (clinical or subclinical), definition of cardiac involvement, and tests used to confirm the diagnosis [3, 7]. Cardiovascular involvement is considered to be one of the major causes of mortality in patients with myositis [8, 9]. Mortality due to myocardial infarction in patients with myositis was reported to be increased by 16 times, especially among female patients [10]. Despite the lack of large epidemiological studies, cardiac involvement has been reported as a cause of death in 10–20% of patients with polymyositis [11, 12]. A number of cases of cardiac and skeletal myositis have been reported in the literature in which an underlying cause was identified. Kerr and Spiera reported six cases of myocarditis as a complication in scleroderma patients with myositis. In contrast to our patient, all of the six patients had an elevated CK, and five of them had reduced LVEF [13]. Infectious agents such as influenza virus and toxoplasma have been reported to cause polymyositis and myocarditis in a 4-year-old and a 13-year-old immunocompetent patient, respectively [14, 15]. Greaves et al. investigated the prevalence of myocarditis and skeletal myositis using CK, CK-MB, and troponin I/T in 152 adults with acute viral infection. The study showed that skeletal muscle injury was far more common than cardiac muscle injury in that cohort of patients [16]. Further literature review revealed a recently reported case of myocarditis and skeletal myositis in a 65-year-old following a seasonal influenza vaccination. Similar to our case, his myocarditis was diagnosed with cardiac MRI and an elevated troponin I, but in contrast to our case, his CK level was markedly elevated [17].

Our case is unique as there was no evidence from the history, clinical examination, or extensive laboratory investigations to indicate a specific aetiology of this man’s myositis. Endomyocardial biopsy is the gold standard test for myocarditis; however, the clinical presentation in conjunction with the raised troponin level and a cardiac MRI demonstrating myocardial muscle oedema in keeping with myocarditis was considered sufficient to make a diagnosis without a myocardial biopsy, since such a procedure would be invasive and not without significant side effects. Consequently, the patient was noted to have calf muscle symptoms and MRI demonstrated skeletal muscle oedema in a distribution in keeping with skeletal muscle myositis. At this juncture, a skeletal muscle biopsy was proposed but the patient was not happy to consent to this procedure. However, in light of the history and clinical and MRI findings, it was considered reasonable to make a diagnosis of skeletal muscle myositis on a background of myocarditis and to treat the patient accordingly.

The first-line treatment of idiopathic inflammatory myositis is a high dose of corticosteroids (60–100 mg), which should be tapered after 4–6 weeks according to response [18]. Most patients require an additional immunosuppressive agent such as methotrexate, azathioprine, or mycophenolate mofetil [18]. There are very few studies comparing immunosuppressant regimes (azathioprine with methotrexate, cyclosporine with methotrexate, and intramuscular methotrexate with oral methotrexate plus azathioprine). They showed no statistically significant difference in efficacy between the treatment regimes [19]. We chose methotrexate due to our extensive experience with the drug and the fact that no trials have shown the superiority of one agent over the other. Other treatment options such as intravenous immunoglobulins, cyclophosphamide, and rituximab can be used but are reserved for severe or refractory cases [18].

In conclusion, we report a rare case of clinically significant cardiac and skeletal myositis whose cause is unclear. In patients with acute myocarditis, it is important to consider the possibility of an associated skeletal myositis when suggestive symptoms are present. MRI can be useful to establish the diagnosis particularly if laboratory tests are not conclusive. Further trials are needed to determine whether cardiac involvement is associated with certain types and subtypes of myositis or not.
Conflicts of Interest
All authors state that they have no conflicts of interest to declare.

References
[1] P. Richardson, W. McKenna, M. Bristow et al., “Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies,” Circulation, vol. 93, no. 5, pp. 841–842, 1996.
[2] O. Leone, J. P. Veinot, A. Angelini et al., “2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology,” Cardiovascular Pathology, vol. 21, no. 4, pp. 245–274, 2012.
[3] J. S. Gottdiener, H. S. Sherber, R. J. Hawley, and W. K. Engel, “Cardiac manifestations in polymyositis,” The American Journal of Cardiology, vol. 41, no. 7, pp. 1141–1149, 1978.
[4] I. E. Lundberg, “Cardiac involvement in autoimmune myositis and mixed connective tissue disease,” Lupus, vol. 14, no. 9, pp. 708–712, 2005.
[5] I. E. Lundberg, “The heart in dermatomyositis and polymyositis,” Rheumatology, vol. 45, Supplement 4, pp. iv18–iv21, 2006.
[6] H. Oppenheim, “Zur dermatomyositis,” Berliner Klinische Wochenschrift, vol. 36, pp. 805–807, 1899.
[7] L. Gonzalez-Lopez, J. I. Gamez-Nava, L. Sanchez et al., “Cardiac manifestations in dermato-polymyositis,” Clinical and Experimental Rheumatology, vol. 14, no. 4, pp. 373–379, 1996.
[8] K. Danko, A. Ponyi, T. Constantin, G. Borgulya, and G. Szegedi, “Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases,” Medicine, vol. 83, no. 1, pp. 35–42, 2004.
[9] A. Bohan, J. B. Peter, R. L. Bowman, and C. M. Pearson, “Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis,” Medicine, vol. 56, no. 4, pp. 255–286, 1977.
[10] R. Devere and W. G. Bradley, “Polymyositis: its presentation, morbidity and mortality,” Brain, vol. 98, no. 4, pp. 637–666, 1975.
[11] S. M. Sultan, Y. Ioannou, K. Moss, and D. A. Isenberg, “Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality,” Rheumatology, vol. 41, no. 1, pp. 22–26, 2002.
[12] M. C. Hochberg, D. Feldman, and M. B. Stevens, “Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature,” Seminars in Arthritis and Rheumatism, vol. 15, no. 3, pp. 168–178, 1986.
[13] L. D. Kerr and H. Spiera, “Myocarditis as a complication in scleroderma patients with myositis,” Clinical Cardiology, vol. 16, no. 12, pp. 895–899, 1993.
[14] S. Tabbutt, M. Leonard, R. I. Godinez et al., “Severe influenza B myocarditis and myositis,” Pediatric Critical Care Medicine, vol. 5, no. 4, pp. 403–406, 2004.
[15] P. K. Paspalaki, E. P. Mihailidou, M. Bitsori, D. Tsagkaraki, and E. Mantzouranis, “Polymyositis and myocarditis associated with acquired toxoplasmosis in an immunocompetent girl,” BMC Musculoskeletal Disorders, vol. 2, no. 1, 2001.
[16] K. Greaves, J. S. Oxford, C. P. Price, G. H. Clarke, and T. Crane, “The prevalence of myocarditis and skeletal muscle injury during acute viral infection in adults,” Archives of Internal Medicine, vol. 163, no. 2, pp. 165–168, 2003.
[17] M. P. Cheng, M. G. Kozeriz, A. A. Ahmadi, J. Kelsall, K. Paquette, and J. M. Onrot, “Post-vaccination myositis and myocarditis in a previously healthy male,” Allergy, Asthma & Clinical Immunology, vol. 12, no. 1, p. 6, 2016.
[18] A. Malik, G. Hayat, S. Kalia, and M. A. Guzman, “Idiopathic inflammatory myopathies: clinical approach and management,” Frontiers in Neurology, vol. 7, p. 64, 2016.
[19] P. A. Gordon, J. B. Winer, J. E. Hoogendijk, and E. H. S. Choy, “Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis,” Cochrane Database of Systematic Reviews, no. 8, article CD003643, 2012.